[关键词]
[摘要]
目的 探讨鼻炎宁胶囊联合糠酸莫米松治疗慢性鼻炎的有效性和安全性。方法 选取2016年5月—2017年5月在太和县人民医院进行治疗的慢性鼻炎患者174例,根据用药方案不同分成对照组和治疗组,每组各87例。对照组患者给予糠酸莫米松鼻喷雾剂,4揿/次,1次/d,症状明显缓解后每鼻孔1揿;治疗组患者在对照组的基础上口服鼻炎宁胶囊,5粒/次,3次/d。两组患者均治疗4周。观察两组患者临床疗效,比较治疗前后两组患者鼻阻力、临床症状评分、生活质量评分、IL-17和IgE水平及不良反应。结果 治疗后,对照组临床总有效率为87.36%,显著低于治疗组的97.70%,两组比较差异具有统计学意义(P < 0.05)。治疗后,两组患者鼻阻力、临床症状评分和生活质量评分均较治疗前显著降低(P < 0.05);且治疗组患者这些指标较对照组降低得更显著(P < 0.05)。治疗后,两组患者IL-17、IgE水平均显著下降(P < 0.05);且治疗组IL-17和IgE水平显著低于对照组(P < 0.05)。治疗期间,治疗组患者不良反应发生率为3.45%,显著低于对照组的12.64%,两组比较差异具有统计学意义(P < 0.05)。结论 鼻炎宁胶囊联合糠酸莫米松鼻喷剂治疗慢性鼻炎具有较好的临床疗效,改善炎症反应水平,具有一定的临床推广应用价值。
[Key word]
[Abstract]
Objective To investigate the clinical efficacy and safety of Biyanning Capsules combined with mometasone furoate in treatment of chronic rhinitis. Methods Patients (174 cases) with chronic rhinitis in Taihe County People's Hospital from May 2016 to May 2017 were divided into control and treatment groups based on different treatments, and each group had 87 cases. Patients in the control group were administered with Mometasone Furoate Aqueous Nasal Spray, 4 presses/time, once daily, 1 press each nostril after symptomatic remission. Patients in the treatment group were po administered with Biyanning Capsules on the basis of the control group, 5 grains/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the nasal resistance, clinical symptom scores, quality of life impact scores, IL-17 and IgE levels, and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 87.36%, which was significantly lower than 97.70% in the treatment group, and there were differences between two groups (P < 0.05). After treatment, the nasal resistance, clinical symptom scores, and quality of life impact scores in two groups were significantly decreased (P < 0.05). And these indexes in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, the IL-17 and IgE levels in two groups were significantly decreased (P < 0.05), and the IL-17 and IgE levels in the treatment group were significantly lower than those in the control group (P < 0.05). During the treatment, the incidence of adverse reactions in the treatment group was 3.45%, which was significantly lower than 12.64% in the control group, with significant difference between two groups (P < 0.05). Conclusion Biyanning Capsules combined with mometasone furoate has good clinical efficacy in treatment of chronic rhinitis, can significantly improve inflammatory responses, which has a certain clinical application value.
[中图分类号]
[基金项目]